Osteonecrosis of the femoral head safely healed with autologous, expanded, bone marrow-derived mesenchymal stromal cells in a multicentric trial with minimum 5 years follow-up
Entity
UAM. Departamento de Cirugía; Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)Publisher
MDPI, Basel, SwitzerlandDate
2021-02-01Citation
10.3390/jcm10030508
Journal of Clinical Medicine 10.3 (2021): 508
ISSN
2077-0383DOI
10.3390/jcm10030508Funded by
The research leading to these results has received funding from the European Research Council under the European Union’s Seventh Framework Programme (FP7/FP7-HEALTH-2009): REBORNE Project, Grant Agreement 241876. Work in EFS and stromalab was also supported by the Agence Nationale pour la Recherche for support of the national infrastructure: “ECELLFRANCE"Project
info:eu-repo/grantAgreement/EC/FP7/241876Editor's Version
https://doi.org/10.3390/jcm10030508Subjects
femoral head osteonecrosis; bone regeneration; expanded MSC; clinical trial; MedicinaRights
© 2021 The authorsAbstract
Background: Osteonecrosis (ON) of the femoral head represents a potentially severe
disease of the hip where the lack of bone regeneration may lead to femoral head collapse and secondary osteoarthritis, with serious pain and disability. The aim of this European, multicentric clinical trial
was to prove safety and early efficacy to heal early femoral head ON in patients through minimally
invasive surgical implantation of autologous mesenchymal stromal cells (MSC) expanded from
bone marrow (BM) under good manufacturing practices (GMP). Methods: Twenty-two patients with
femoral head ON (up to ARCO 2C) were recruited and surgically treated in France, Germany, Italy
and Spain with BM-derived, expanded autologous MSC (total dose 140 million MSC in 7 mL). The
investigational advanced therapy medicinal product (ATMP) was expanded from BM under the
same protocol in all four countries and approved by each National Competent Authority. Patients
were followed during two years for safety, based on adverse events, and for efficacy, based on clinical
assessment (pain and hip score) and imaging (X-rays and MRIs). Patients were also reviewed after
5 to 6 years at latest follow-up for final outcome. Results: No severe adverse event was recalled as
related to the ATMP. At 12 months, 16/20 per protocol and 16/22 under intention-to-treat (2 drop-out
at 3 and 5 months) maintained head sphericity and showed bone regeneration. Of the 4 hips with ON progression, 3 required total hip replacement (THR). At 5 years, one patient (healed at 2 years
visit) was not located, and 16/21 showed no progression or THR, 4/21 had received THR (all in the
first year) and 1 had progressed one stage without THR. Conclusions: Expanded MSCs implantation was safe. Early efficacy was confirmed in 80% of cases under protocol at 2 years. At 5 years, the overall results were maintained and 19% converted to THR, all in the first year
Files in this item
Google Scholar:Gómez-Barrena, Enrique
-
Padilla-Eguiluz, Norma G.
-
Rosset, Philippe
-
Hernigou, Philippe
-
Baldini, Nicola
-
Ciapetti, Gabriela
-
Gonzalo-Daganzo, Rosa M.
-
Avendaño Solá, Cristina
-
Rouard, Hélène
-
Giordano, Rosaria
-
Dominici, Massimo
-
Schrezenmeier, Hubert
-
Layrolle, Pierre
-
REBORNE Consortium
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Feasibility and safety of treating non-unions in tibia, femur and humerus with autologous, expanded, bone marrow-derived mesenchymal stromal cells associated with biphasic calcium phosphate biomaterials in a multicentric, non-comparative trial
Gómez-Barrena, Enrique; Rosset, Philippe; Gebhard, Florian; Hernigou, Philippe; Baldini, Nicola; Rouard, Hèlene; Sensebé, Luc; Gonzalo-Daganzo, Rosa M.; Giordano, Rosaria; Padilla-Eguiluz, Norma; García Rey, Eduardo; Cordero Ampuero, José
; Rubio-Suárez, Juan Carlos; Stanovici, Julien; Ehrnthaller, Christian; Huber-Lang, Markus; Flouzat-Lachaniette, Charles Henri; Chevallier, Nathalie; Donati, Davide Maria; Ciapetti, Gabriela; Fleury, Sandrine; Fernández, Manuel-Nicolás; Cabrera, José-Rafael; Avendaño Solá, Cristina
; Montemurro, Tiziana; Panaitescu, Carmen; Veronesi, Elena; Rojewski, Markus Thomas; Lotfi, Ramin; Dominici, Massimo; Schrezenmeier, Hubert; Layrolle, Pierre
2018 -
Transportation conditions for prompt use of Ex Vivo expanded and freshly harvested clinical-grade bone marrow mesenchymal stromal/stem cells for bone regeneration
Veronesi, Elena; Murgia, Alba; Caselli, Anna; Grisendi, Giulia; Piccinno, Maria Serena; Rasini, Valeria; Giordano, Rosaria; Montemurro, Tiziana; Bourin, Philippe; Sensebé, Luc; Rojewski, Markus T.; Schrezenmeier, Hubert; Layrolle, Pierre; Ginebra, Maria Pau; Panaitescu, Carmen Bunu; Gómez-Barrena, Enrique; Catani, Fabio; Paolucci, Paolo; Burns, Jorge S.; Dominici, Massimo
2014-03-01 -
Implantation of autologous expanded mesenchymal stromal cells in hip osteonecrosis through percutaneous forage: Evaluation of the operative technique
Gómez‐Barrena, Enrique; Padilla‐Eguiluz, Norma G.; REBORNE Consortium
2021-02-12